Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer

18Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Tumor necrosis factor (TNF) receptor type II (TNFR2) is expressed in various tumor cells and some immune cells, such as regulatory T cells and myeloid-derived suppressing cells. TNFR2 contributes a lot to the tumor microenvironment. For example, it directly promotes the occurrence and growth of some tumor cells, activates immunosuppressive cells, and supports immune escape. Existing studies have proved the importance of TNFR2 in cancer treatment. Here, we reviewed the activation mechanism of TNFR2 and its role in signal transduction in the tumor microenvironment. We summarized the expression and function of TNFR2 within different immune cells and the potential opportunities and challenges of targeting TNFR2 in immunotherapy. Finally, the advantages and limitations of TNFR2 to treat tumor-related diseases are discussed, and the problems that may be encountered in the clinical development and application of targeted anti-TNFR2 agonists and inhibitors are analyzed.

Cite

CITATION STYLE

APA

Li, M., Zhang, X., Bai, X., & Liang, T. (2022, April 14). Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2022.862154

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free